Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations

• Published in: Clinical cancer research 2020-06, Vol.26 (12), p.2972-2985
• Main Authors: Aguilera, Todd A, Elghonaimy, Eslam A, Shehade, Hussein, Rafat, Marjan, Castellini, Laura, Jiang, Dadi, Kariolis, Mihalis, Koong, Albert C, Le, Quynh-Thu, Ellies, Lesley G, Rankin, Erinn B, Graves, Edward E, Giaccia, Amato J
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Breast Neoplasms - immunology; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Cell Proliferation; Female; Humans; Immunotherapy - mortality; Mice; Mice, Inbred C57BL; Mice, Transgenic; Radioimmunotherapy - mortality; Radiotherapy - mortality; Tumor Cells, Cultured; Xenograft Model Antitumor Assays
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-19-4220

To investigate how induced tumor heterogeneity influences immune responses to radiotherapy with different proportions of mixed immune-responsive and unresponsive tumor cells in a triple-negative breast cancer model. It is hypothesized that studying the immune environment of mixed tumors and responses to radiotherapy could nominate immune active therapies to enhance immune responses after radiotherapy. Evaluate efficacy and immune responses generated by radiotherapy in tumors with different proportions of immunologically responsive and unresponsive tumor cells. Then study the cellular responses and transcriptomic differences between the tumors to nominate immunotherapy combinations with radiotherapy and evaluate the combination. The addition of the responsive cells to unresponsive tumors led to a greater than expected therapeutic response to radiotherapy with both innate and adaptive immune components. There was a distinct change in myeloid cells, greater inflammatory macrophage activity, and enhanced antigen presentation with responsive cells after radiotherapy. Because differences in matrix components, cell adhesion biology, and innate immune signaling correlated with myeloid cell response and phenotype, we hypothesized that radiotherapy combined with CD40 agonist antibody would sensitize unresponsive tumors. The combination therapy resulted in improved innate and adaptive immune response. Importantly, CD40 treatment increased tumor response to radiotherapy and protected against metastatic spread in a metastatic model. These data combined with transcriptomics from human patients support radiotherapy and myeloid cell targeting for immunologically cold tumors. The established study model presents opportunities to investigate the complex overlapping biologic mechanisms that limit immunotherapy and to implement radiotherapy with different immunotherapy combinations.